Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | |||||||||||||
| PMID | |||||||||||||
| Authors | Feng Wang | ||||||||||||
| Title | Abstract 4903: AXL inhibition overcomes erlotinib resistance in AXL-activated non-small cell lung cancer cells | ||||||||||||
|
|||||||||||||
| URL | http://cancerres.aacrjournals.org/content/78/13_Supplement/4903 | ||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|---|---|---|---|---|
| AXL | A273V | missense | unknown | AXL A273V lies within fibronectin type-III domain 1 of the Axl protein (UniProt.org). A273V has been associated with resistance to EGFR inhibitors (Cancer Res 2018;78(13 Suppl): nr 4903), but has not been biochemically characterized and therefore, its effect on Axl protein function is unknown (PubMed, Jan 2026). | Y |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL A273V | lung non-small cell carcinoma | predicted - resistant | Erlotinib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of AXL A273V in non-small cell lung cancer cells conferred resistance to Tarceva (erlotinib) in culture (Cancer Res 2018;78(13 Suppl): nr 4903). | detail... |